Search

everythinglearnresearchcommunity

for

Search:↓

New cytokine-targeted therapies show promise for treating alopecia areata.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

The document is a detailed medical reference on skin and genetic disorders.

Cyclosporine A slows down hair loss from chemotherapy in mice, while dexamethasone increases hair loss but speeds up regrowth.

ILC1-like cells can independently cause alopecia areata by affecting hair follicles.

Mutations in specific keratin genes cause improper hair structure in mice due to faulty keratin protein assembly.

New gene variants linked to a rare inherited hair loss disorder were found in three Chinese families.

The absence of functional sebaceous glands causes hair follicle destruction and scarring alopecia.

The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.

Changes in the SREBF1 gene cause a rare genetic skin and hair disorder.

Platelet-rich plasma (PRP) is a simple, cost-effective treatment that promotes hair growth and reduces hair loss, with high patient satisfaction.

Diagnosing diffuse alopecia, a hair loss condition, can be challenging and may require a scalp biopsy or tracking the disease's progression when symptoms and skin tests aren't enough.

sPLA2-IIE is crucial for normal hair follicle structure and skin health.

Thyroid diseases may contribute to autoimmune skin diseases, and more research is needed on their relationship.

The document concludes that changes in eyelashes and eyelid skin can indicate various local and systemic diseases.

Our microbiome may affect the development of the hair loss condition Alopecia Areata, but more research is needed to understand this relationship.

Wound healing can help prevent hair loss from chemotherapy in young rats by increasing interleukin-1β signaling.

Platelet-rich plasma (PRP) shows promise in skin and hair treatments but results vary with preparation methods.

Different causes of beard hair loss have various treatments, including medications, lifestyle changes, and procedures to stimulate hair growth.

Human dental pulp stem cell-conditioned medium, especially from hypoxic conditions, may help treat chemotherapy-induced hair loss and does not increase cancer risk.

WNT10A mutations cause varied symptoms in patients with odonto-onycho-dermal dysplasia.

Eyelash alopecia areata often goes undiagnosed and can lead to complete eyelash regrowth, especially in younger patients.

Scalp cooling can help prevent hair loss from chemotherapy, but treatment should be tailored to the individual and more research is needed.

Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.

Different types of persistent hair loss after chemotherapy respond differently to treatments.

Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.

The scalp fat tissue of men with hair loss shows changes in gene activity that may contribute to their condition.

Thallium, mercury, selenium, and colchicine strongly cause hair loss.

A specific pathway involving AR, miR-221, and IGF-1 plays a key role in causing common hair loss.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.